The objective of this study was to review loss of response and need for adalimumab dose
intensification in adult and pediatric patients with Crohn's disease. Studies were identified …

Background and aims: Adalimumab is efficacious in inducing and maintaining remission in
Crohn's disease but dose escalation is needed in 30–40% after 1 year. Attempts for dose de …

Background Adalimumab is effective for the induction and maintenance of remission in
Crohn's disease (CD)‐patients. Aim To find predictors for adalimumab dose escalation at …

Background Data from CHARM, a 56-week, randomized controlled trial of adalimumab for
patients with moderately to severely active Crohn's disease (CD), were used to evaluate …

OBJECTIVES: To compare outcomes of induction dosing followed by continuous
adalimumab treatment with those of induction dosing with reinitiation of adalimumab (in the …

Background There is clear benefit from combination therapy with infliximab and
immunosuppressive drugs (IS), but few data are available for adalimumab (ADA). Aim To …

Abstract Background and Aims Adalimumab is an effective therapy for induction and
maintenance of Crohn's disease. However, results in clinical trials don't necessarily reflect …

Background & Aims Dose-optimization strategies for biologic therapies in Crohn's disease
(CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction …

Background Crohn's disease patients who have lost response to 5 mg/kg of infliximab may
regain response by increasing the dose of infliximab to 10 mg/kg. Alternatively, adalimumab …

OBJECTIVES: To review the frequency with which infliximab loses its effect and dose
“intensification” is required for Crohn's disease treatment. METHODS: Bibliographical …